Triple Negative Breast Cancer – Leronlimab Plus Chemo Appears to Prolong Survival
Straight to the Point in Triple Negative Breast Cancer Leronlimab (PRO 140) has demonstrated promising preliminary results in a phase 1b/2 clinical trial (NCT03838367) for
Triple Negative Breast Cancer and a New Drug, Trilaciclib
Overview Doctors often struggle with treating advanced stages of breast cancer, especially Triple Negative Breast Cancer, TNBC. When the tumor is located in a confined
The standard protocol – do the same and get the same. Upsetting!
The treatment that is given “according to the book” to everyone, is called in professional language “the standard protocol”. LB, our client, 62, was diagnosed
Prostate Cancer Breakthrough Drug Combination for Metastatic Patients
Background Despite the advances and strides that modern medicine has made, prostate cancer treatment options remain to be fairly reserved. However, the day is finally
Breast Cancer – The Potential Use of SYD985
Overview – Breast cancer and [vic-]trastuzumab duocarmazine (SYD985) and In a recent press release by Byondis, the pharmaceutical company expressed excitement and optimism about the
Fecal Microbiota Transplant in melanoma patients
Background The utilization of FMT can influence how metastatic melanoma patients respond to anti-PD-1 immunotherapy. Numerous microbes inhabit the human gut. The colon itself has
Liver cancer – New and effective treatment with Toripalimab and HAIC Plus Lenvima
Background – New option for Liver cancer Hepatic Arterial Infusion Chemotherapy, HAIC, is a medical procedure that delivers chemotherapy directly to the liver and widely
Gastric and GEJ cancers – Keytruda to HER2+ patients, improves outcomes
Background The first findings of KEYNOTE-811, an ongoing, global phase III trial, found that the addition of Keytruda to Herceptin plus chemotherapy for first-line treatment
Pancreatic Cancer – Nadunolimab brings positive results
Background Pancreatic cancer is an aggressive type of cancer with very little treatment options that are mostly disappointing especially in the advanced stages of disease,
Glioblastoma and all gliomas – Tafinlar plus Mekinist, a durable benefit
Background – Glioblastoma and BRAF BRAFV600E mutations are rarely encountered in adult glioblastoma with an incidence ranging from less than 1% to 8%. But young
Lung Cancer Treated with Electric Fields – Strongly Positive Results
Background Interim analysis of the phase 3 LUNAR trial led to a recommendation to reduce the number of lung cancer patients required. This recommendation is
